Sales of Pfizer’s antiviral drug Paxlovid have leapfrogged a rival pill developed by Merck and now dominate the Covid-19 treatments market, but slower than expected patient uptake could dent sales over the next six months and beyond.
Airfinity, a health data analytics group, said recent data showed the whirlwind pace of new supply deals signed by Pfizer had begun to slow due to the lacklustre roll out of a treatment billed as a key tool to help quell the pandemic.
By the end of 2022 there could be a surplus of up to 70mn courses of Paxlovid on the global market following a ramp up in production by Pfizer and weak demand for a treatment that US President Joe Biden is currently taking to fight his Covid infection.
您已阅读16%（719字），剩余84%（3778字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。